Testing ways to predict opioid withdrawal during a taper
Treatments studied
Part of Mental health clinical trials.
This Phase 2 study looks at what opioid withdrawal looks like in the body and whether they can measure it in a meaningful way. You may join if you have an opioid use disorder, can show physical dependence, and are interested in tapering (gradually reducing) opioids under study care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old
- A urine test must show opioids are in your system
- You currently have opioid use disorder and signs your body is physically dependent on opioids
- You are willing and interested in doing an opioid taper (gradually reducing opioids)
- You are not pregnant and not breastfeeding
- You are not currently in methadone or buprenorphine maintenance treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether buspirone can help reduce symptoms during opioid detox (withdrawal). You may be able to take part if you have opioid withdrawal and are planning medically supervised detox.
This study is developing a questionnaire to better measure opioid withdrawal symptoms. By participating, you'll help create a tool that may improve how withdrawal is assessed in future care and research.
This trial tests if a ketone supplement can help reduce cravings during opioid withdrawal treatment. Participants take the supplement daily and are monitored for changes in craving and withdrawal symptoms.
This study tests whether the medication suvorexant can reduce drug cravings in people with opioid use disorder. You will take either suvorexant or a placebo and have your cravings measured in a safe setting.
This trial tests whether a combination of buprenorphine (through your care plan) and a monthly extended-release naltrexone (XR-NTX) shot can help prevent opioid relapse. It may help people who are ready to move toward a naltrexone-based relapse-prevention treatment after detox.
This trial tests a physical device (ADTPM 1) to help manage withdrawal symptoms in people who are dependent on opioids. The goal is to see if the device can safely reduce withdrawal discomfort.
Hear when a new Opioid Withdrawal trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.